Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$22.8B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. With a market cap of $23 billion, it plays a significant role in the healthcare sector, particularly in vaccine development and personalized medicine.

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the demand for BioNTech's products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1-2026, BioNTech reported an EPS of -$2.28, which was better than the expected -$2.52, resulting in a positive surprise of 9.45%. However, the stock fell 3.88% the following day, indicating investor concerns.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on BioNTech's financial recovery and product pipeline. The company has faced challenges in recent quarters, leading to cautious sentiment.

Bull Case

If BioNTech can demonstrate improved earnings and revenue growth, it could signal a turnaround and restore investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company continues to report losses and fails to meet expectations, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

Given the company's recent history of losses, the EPS figure will be crucial in assessing whether BioNTech is on a path to recovery.

How is the demand for BioNTech's vaccines and therapies trending?

Understanding the demand will provide insights into the company's revenue potential and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioNTech's recovery based on recent product developments and partnerships that could drive future revenue.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect more volatility than what has been historically realized.

Recent earnings surprises, despite losses, suggest that the company may be closer to a turnaround than analysts expect.

Key Risk

If the EPS comes in significantly better than expected, it could shift the narrative around BioNTech's recovery.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioNTech can stabilize its financial performance and regain investor trust.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving towards breakeven, would confirm the bull case.

Bear Confirmed If

Continued losses beyond -$2.28 EPS would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by an average of 2.09% on the following day, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

Should the company miss expectations, history indicates a potential decline of around 7.43%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance product offerings.
2Details on the pipeline for new therapies and vaccines.
3Insights into cost management strategies to reduce losses.
4Trends in demand for existing products and how they are impacting revenue.
5Management's outlook on future earnings and revenue growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the demand for BioNTech's products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on BioNTech's financial recovery and product pipeline. The company has faced challenges in recent quarters, leading to cautious sentiment.

Bull Case

If BioNTech can demonstrate improved earnings and revenue growth, it could signal a turnaround and restore investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company continues to report losses and fails to meet expectations, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

Given the company's recent history of losses, the EPS figure will be crucial in assessing whether BioNTech is on a path to recovery.

How is the demand for BioNTech's vaccines and therapies trending?

Understanding the demand will provide insights into the company's revenue potential and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioNTech's recovery based on recent product developments and partnerships that could drive future revenue.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect more volatility than what has been historically realized.

Recent earnings surprises, despite losses, suggest that the company may be closer to a turnaround than analysts expect.

Key Risk

If the EPS comes in significantly better than expected, it could shift the narrative around BioNTech's recovery.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioNTech can stabilize its financial performance and regain investor trust.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving towards breakeven, would confirm the bull case.

Bear Confirmed If

Continued losses beyond -$2.28 EPS would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by an average of 2.09% on the following day, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

Should the company miss expectations, history indicates a potential decline of around 7.43%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance product offerings.
2Details on the pipeline for new therapies and vaccines.
3Insights into cost management strategies to reduce losses.
4Trends in demand for existing products and how they are impacting revenue.
5Management's outlook on future earnings and revenue growth.